FDA Real-Time Clinical Trials: 4 Key Packaging Takeaways for Pharma and Biopharma

On April 28, 2026, the FDA announced major steps toward implementing real-time clinical trials (RTCT), including two successful proof-of-concept collaborations with AstraZeneca and Amgen and an upcoming pilot program launching this summer. The goal: continuous data sharing between sponsors and the FDA to accelerate promising therapies to patients without sacrificing safety or efficacy. 

For pharmaceutical and biopharmaceutical companies, this is more than a regulatory update. As drug development timelines compress, pharmaceutical packaging decisions cannot lag behind clinical progress. Here are 4 key takeaways for packaging teams. 
 

Takeaway 1: Get Packaging in the Room Earlier

Pharmaceutical packaging has historically been treated as a late-stage activity. That approach does not hold up under accelerated clinical trial timelines. Material selection, compatibility testing, supplier engagement, packaging configuration, and for combination products, delivery system decisions, all need to happen earlier in drug development, ideally by Phase II. 

Under traditional timelines, packaging teams had room to course-correct if stability or compatibility issues surfaced late in development. That buffer is shrinking. A packaging problem discovered at the wrong moment can jeopardize FDA approval or delay commercialization entirely. 
 

Takeaway 2: Supplier Readiness is Now a Business Risk

Accelerated FDA approval timelines create a new pressure point: packaging supplier readiness. A packaging component that works in clinical development may not be commercially scalable. If your supplier is not prepared for commercial volumes when approval comes faster than expected, you have a launch problem. 

Procurement, packaging engineering, and supplier timelines need to move in lockstep with clinical development. Evaluating commercial scalability upfront, not after approval, is now a critical part of the pharmaceutical packaging strategy. 
 

Takeaway 3: There is Less Room to Course Correct

Real-time clinical review reduces the buffer traditionally available to catch packaging-related risks: material interactions, extractables and leachables concerns, moisture or light sensitivity, and drug product stability issues. Under older drug development models, packaging teams had time to change materials, adjust storage conditions, or redesign packaging systems. That flexibility is no longer a given. 

Stability studies, compatibility testing, and packaging risk assessments need earlier visibility and cross-functional coordination to match the pace of the accelerated clinical program. 
 

Takeaway 4: Packaging Strategy Needs to be a Cross-Functional Priority

Real-time clinical trials mean that data, decisions, and development milestones are moving faster across the entire organization. Packaging cannot operate in a silo while clinical, regulatory, and commercial teams accelerate around it. 

Packaging engineers, procurement, regulatory affairs, and manufacturing readiness teams need to be aligned early and stay aligned throughout development. The companies best positioned for accelerated approval pathways will be the ones treating pharmaceutical packaging strategy as an organizational priority from day one, not a downstream handoff. 
 

The Bottom Line

The FDA's push toward real-time clinical trials reflect a broader shift toward collaborative, data-driven drug development. For pharmaceutical and biopharmaceutical packaging teams, the message is clear: packaging strategy, material decisions, supplier readiness, and cross-functional alignment need to keep pace with clinical timelines from the start. 

At Adept, our pharmaceutical packaging consultants help companies align packaging strategy with accelerated development timelines, from clinical development through commercial launch. Contact us to talk through what this FDA shift means for your packaging program. 
 

About the Authors: 

Jim Regan, Head of Packaging Consulting Services, Pharmaceutical at Adept Group
With more than 35 years of experience in pharmaceutical and over-the-counter packaging design and development, Jim is a recognized leader in the global packaging industry. His expertise spans packaging components and systems, regulatory compliance, supplier management, sterile injectables, vaccines, gene therapy, solid oral dose products, and Rx-to-OTC switches. He has a proven track record of leading global teams, shaping packaging strategy, and driving cost savings and operational excellence across multinational organizations. 

Matt Peters, Account Executive, Life Sciences at Adept Group
Focused on supporting pharmaceutical, medical device, biotech, and healthcare organizations with packaging strategy, sustainability initiatives, and operational improvement efforts across the product lifecycle. He works closely with industry leaders to support initiatives related to EPR, PPWR, packaging optimization, supply chain strategy, and evolving market demands. Drawing from experience in consultative sales and business development, Matt helps customers uncover opportunities for cost savings, packaging innovation, and process improvements while delivering practical solutions aligned with both business objectives and patient-focused outcomes.